Warfarin resistance

      This paper is only available as a PDF. To read, Please Download here.


      Studies are presented of a patient who was resistant to warfarin and phenindione anticoagulants. There was a strikingly rapid rate of warfarin clearance from plasma: 10.7 per cent per hour in contrast to the normal rate of 1.6 per hour.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Boyles P.W.
        Antithrombotic Therapy.
        in: Grune & Stratton, Inc, New York1959: 25
        • Soulier J.P.
        Dicumarol resistance.
        in: Macmillan R.L. Mustard J.F. Anticoagulants and Fibrinolysins: An International Symposium. Lea & Febiger, Philadelphia1961: 201
        • Aravanis C.
        • Evangelou I.
        • Michaelides G.
        Clinical experience with the anticoagulant Panwarfin (warfarin sodium).
        Angiology. 1963; 14: 325
        • O'Reilly R.A.
        • Aggeler P.M.
        • Hoag M.S.
        • Leong L.S.
        • Kropatkin M.L.
        Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred.
        New England J. Med. 1964; 271: 809
        • Wanntorp H.
        Studies on chemical determination of warfarin and coumachlor and their toxicity for dog and swine.
        Acta pharmacol. toxicol. 1959; 16: 1
        • Lund M.
        Resistance to warfarin in the common rat.
        Nature. 1964; 203: 778
        • Millar G.J.
        • Jaques L.B.
        • Henriet M.
        The prothrombin time response of rabbits to Dicumarol.
        Arch. internat. pharmacodyn. 1964; 150: 197
        • Rowe F.P.
        • Redfern R.
        Toxicity tests of suspected resistant house mice (Mus musculus L.).
        J. Hyg. 1965; 63: 417
        • Link K.P.
        The anticoagulant from spoiled sweet clover hay.
        Harvey Lect. 1943; 39: 162
        • Evans D.A.P.
        (Quoted by O'Reilly, R. A. and Aggeler, P. M.)Coumarin anticoagulant drugs: hereditary resistance in man. 6th ed. Fed. Proc.24. 1965: 1266
        • Levine W.G.
        Anticoagulants. Heparin, bishydroxy-coumarin, and congeneric substitutes.
        in: Goodman L.S. Gilman A. The Pharmacological Basis of Therapeutics. Macmillan Co, New York1965: 1453
        • Jones R.J.
        • Cohen L.
        Sodium dextro-thyroxine in coronary disease and hypercholesteremia.
        Circulation. 1961; 24: 164
        • Owens J.C.
        • Neely W.B.
        • Owen W.R.
        Effect of sodium dextrothyroxine in patients receiving anticoagulants.
        New England J. Med. 1962; 266: 76
        • Walters M.B.
        The relationship between thyroid function and anticoagulant therapy.
        Am. J. Cardiol. 1963; 11: 112
        • Oliver M.F.
        • Roberts S.D.
        • Hayes D.
        • Pantridge J.F.
        • Suzman M.M.
        • Bersohn I.
        Effect of atromid ethyl chlorophenoxyiso-butyrate on anticoagulant requirements.
        Lancet. 1963; 1: 143
        • Nikkila E.A.
        • Pelkonen R.
        Serumlipid reducing agents and anticoagulant requirements.
        Lancet. 1963; 1 (Letter.): 332
        • Furman R.H.
        • Howard R.P.
        • Alaupovic P.
        Serumlipid reducing agents and anticoagulant requirements.
        Lancet. 1963; 1 (Letter.): 893
        • Shapiro S.
        • Weiner M.
        Coagulation, Thrombosis, and Dicumarol.
        in: Brooklyn Medical Press, New York1949: 70
        • Soulier J.P.
        Résistance aux dicoumariniques.
        Path. et Biol. 1960; 8: 985
        • Matsumura T.
        Variations in response to the anticoagulant dicumarol. (The role of vitamin K synthesized by intestinal bacterial flora.).
        J. Jap. Soc. Int. Med. 1964; 53: 859
        • Olwin J.H.
        Unusual experiences with anticoagulant therapy and the principles they represent.
        in: Koller T. Merz W.R. Thrombosis and Embolism. Proceedings of the First International Conference. Benno Schwabe & Co, Basel1955: 713
        • Lowenthal J.
        • Fisher L.M.
        The effect of thyroid function on the prothrombin time response to warfarin in rats.
        Experientia. 1957; 13: 253
        • Overman R.S.
        • Stahman M.A.
        • Link K.P.
        Studies on the hemorrhagic sweet clover disease. VIII. The effect of 2-methyl-1, 4-naphthoquinone and L-ascorbic acid upon the action of 3, 3′-methylenebis (4-hydroxycoumarin) on the prothrombin time of rabbits.
        J. Biol. Chem. 1942; 145: 155
        • Baumann C.A.
        • Field J.B.
        • Overman R.S.
        • Link K.P.
        Studies on the hemorrhagic sweet clover disease. X. Induced vitamin C excretion in the rat and its effect on the hypoprothrombinemia caused by 3, 3′-methylenebis (4-hydroxycoumarin).
        J. Biol. Chem. 1942; 146: 7
        • Field J.B.
        • Larsen E.G.
        • Spero L.
        • Link K.P.
        Studies on the hemorrhagic sweet clover disease. XIV. Hyperprothrombinemia induced by methylxanthines and its effect on the action of 3, 3′-methylenebis (4-hydroxycoumarin).
        J. Biol. Chem. 1944; 156: 725
        • Chatterjea J.B.
        • Salomon L.
        Antagonistic effect of ACTH and cortisone on the anticoagulant activity of ethyl biscoumacetate.
        Brit. M. J. 1954; 2: 790
        • Avellanda M.
        Interferencia de los barbituricos en la accion del Tromexan.
        Medicina, Buenos Aires. 1955; 15: 109
        • Oakley D.P.
        • Lautch H.
        Haloperidol and anticoagulant treatment.
        Lancet. 1963; 2 (Letter.): 1231
        • Catalano P.M.
        • Cullen S.I.
        Warfarin, antagonism by Griseofulvin.
        Clin. Res. 1966; 14 (Abstract.): 266
        • O'Reilly R.A.
        • Aggeler P.M.
        • Hoag M.S.
        • Leong L.
        Studies on the coumarin anticoagulant drugs. The assay of warfarin and its biologic application.
        Thromb. et Diath. Haemorrh. 1962; 8: 82
        • Quick A.J.
        The clinical application of the hippuric acid and the prothrombin tests.
        Am. J. Clin. Path. 1940; 10: 222
        • Ware A.G.
        • Stragnell R.
        An improved one stage prothrombin method.
        Am. J. Clin. Path. 1952; 22: 791
        • Spaet T.H.
        • Cintron J.
        Pathways to blood coagulation product formation.
        Blood. 1963; 21: 745
        • Denson K.W.
        The specific assay of Prower-Stuart factor and factor VII.
        Acta haemat. 1961; 25: 105
        • Proctor R.R.
        • Rapaport S.I.
        The partial thromboplastin time with kaolin.
        Am. J. Clin. Path. 1961; 36: 212
        • O'Reilly R.A.
        • Aggeler P.M.
        • Leong L.S.
        Studies on the coumarin anticoagulant drugs. The pharmacodynamics of warfarin in man.
        J. Clin. Invest. 1963; 42: 1542
        • Weiner M.
        • Brodie B.B.
        • Burns J.J.
        A comparative study of hypoprothrombinemic agents. The physiological disposition and chemical pharmacology of coumarin and indanedione compounds.
        in: Koller T. Merz W.R. Thrombosis and Embolism. Proceedings of the First International Conference. Benno Schwabe & Co, Basel1955: 181
        • Aggeler P.M.
        • O'Reilly R.A.
        The pharmacological basis of oral anticoagulant therapy.
        in: Koller F. Duckert F. Streuli F. Pathogenesis and Treatment of Thromboembolic Diseases. F. K. Schattauer-Vorlag, Basel1966: 227
        • Nelson E.
        Kinetics of drug absorption, distribution, metabolism, and excretion.
        J. Pharm. Sc. 1961; 50: 181
        • Brodie B.B.
        • Burns J.J.
        • Weiner M.
        Metabolism of drugs in subjects with Laennec's cirrhosis.
        Med. Exper. (Basel). 1959; 1: 290
        • O'Reilly R.A.
        • Kowitz P.E.
        Interaction of human albumin and warfarin sodium.
        Clin. Res. 1966; 14 (Abstract.): 149
        • Gillette J.R.
        Reversible binding as a complication in relating the in vitro effect of drugs to their in vivo activity.
        in: Drugs and Enzymes. 6th ed. Proceedings of the Second International Pharmacological Meeting. vol. 4. Pergamon Press, Inc, New York1965: 9
        • Evans D.A.P.
        • White T.A.
        Human acetylation polymorphism.
        J. Lab. & Clin. Med. 1964; 63: 394